 - Histologically or cytologically confirmed diagnosis of advanced or recurrent Stage IIIB not amenable for multimodality treatment or metastatic Stage IV NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry IHC test. Sufficient tumor tissue available to perform ALK IHC is required. Ventana IHC testing will be performed at the designated central laboratory 